Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Glioma
ADR ID BADD_A01844
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.30      Nervous system neoplasms malignant and unspecified NEC
16.30.01      Nervous system neoplasms unspecified malignancy NEC
16.30.01.004      Glioma
17      Nervous system disorders
17.20      Nervous system neoplasms malignant and unspecified NEC
17.20.01      Nervous system neoplasms unspecified malignancy NEC
17.20.01.004      Glioma
Description Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) [MeSH]
MedDRA Code 10018338
MeSH ID D005910
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Diencephalic glioma | Glioma | Infant-type hemispheric glioma | Gliomas | Glial Cell Tumors | Glial Cell Tumor | Tumor, Glial Cell | Tumors, Glial Cell | Mixed Glioma | Glioma, Mixed | Gliomas, Mixed | Mixed Gliomas | Malignant Glioma | Glioma, Malignant | Gliomas, Malignant | Malignant Gliomas
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00110Aminolevulinic acid--
BADD_D00364Carboplatin0.000728%
BADD_D00566Dabrafenib0.000168%
BADD_D00858Everolimus0.000153%
BADD_D00989Gadolinium--
BADD_D01238Lacosamide0.002194%
BADD_D01265Levetiracetam0.000119%
BADD_D01418Methotrexate0.000114%
BADD_D02150Temozolomide0.000280%
BADD_D02257Trametinib0.000616%
BADD_D02464Fingolimod0.000482%
BADD_D02526Larotrectinib0.000168%
The 1th Page    1    Total 1 Pages
ADReCS-Target
ADR Term Drug Name Target